NCT03984448 2026-04-13
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas
National Cancer Institute (NCI)
Phase 2/3 Active not recruiting
National Cancer Institute (NCI)
Children's Cancer Group, China
University of Birmingham
Children's Oncology Group
Beijing Pearl Biotechnology Limited Liability Company
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Institut Curie